- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03681600
Observatory of the Quality of Surgical Procedures for Digestive Cancers (Obchir)
Observatory of the Quality of Surgical Procedures for Digestive Cancers: Pilot Project.
Surgery for digestive cancers is managed according to quality standards, validated by the scientific community. Despite the diffusion of these standards through the benchmarks of good practice, the results of the surgery remain disparate.
In many countries, this "inequality of opportunity" has justified the establishment of quality assurance systems to measure the results of surgery for one or more localizations of digestive cancer.
These surgical audit experiments have shown a positive, rapid and cost-effective impact on complication rates, recurrence rates and overall survival even in the absence of interventional measures. The data collected also helped to improve the management of subgroups of patients usually excluded from clinical trials.
In Morocco, the National Cancer Prevention and Control Plan provides for the establishment of a quality assurance system with the introduction of a system for monitoring and evaluating the care of patients. This pilot project is part of this framework, for the group of patients who are candidates for surgery for digestive cancers.
Studie Overzicht
Toestand
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
-
Oujda, Marokko
- Regional center of oncology, surgical department
-
Rabat, Marokko, 10100
- Ibn Sina Hospital, Surgical department A
-
Rabat, Marokko, 10100
- Ibn Sina Hospital, Surgical department C
-
-
Please Enter The State Or Province
-
Rabat, Please Enter The State Or Province, Marokko, 10100
- National Institut of Oncology, Surgical oncology department
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- patients operated for a digestive cancer, proven or suspected, in a curative or palliative intent In elective situation: inclusion from surgery programming In emergent situation: inclusion no later than 72 hours after surgery
- Cancer proven or suspected in the following digestive tract: colon, appendix, anus, rectum, esophagus, stomach, eso-gastric junction, bile ducts, ampulla of Vater , pancreas, duodenum, small intestine and liver.
- Patient willing and able to agree to participate in the study
Exclusion Criteria:
Patient whose surgical intervention is indicated for:
- a condition that is not a digestive tract cancer, including whether retrospectively surgical exploration and / or histological examination reveals digestive localization cancer
- proven or suspected cancer of non-digestive location
- a proven or suspected cancer of peritoneal localization
- Patient whose surgical intervention is indicated for a progressive disease or a local recurrence proven or suspected of a digestive localization cancer having already been the resected (with the exception of situations of iterative liver resection for liver metastasis hepatic and recovery of the tumor bed after the discovery of vesicular cancer on cholecystectomy specimen)
- Patients whose intervention is for diagnostic purposes without any curative or palliative intention
- Patients whose surgery is a liver transplant
- Patients whose surgical intervention is local destruction (radiofrequency, microwaves) exclusively by percutaneous approach (without laparotomy or laparoscopy)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
90-day Mortality rate
Tijdsspanne: 90 days from surgery
|
Death within 90 days of surgical procedure
|
90 days from surgery
|
|
90-day Complication rate
Tijdsspanne: 90 days from surgery
|
Defined with by Clavien-Dindo grade I to IV within90 days of surgical procedure
|
90 days from surgery
|
|
3-year Overall survival
Tijdsspanne: from the date of operation to date of death from any cause, whichever came first, assessed up to 3 year
|
Overall survival is defined as time from initiation to death of any cause within 3years of surgical procedure
|
from the date of operation to date of death from any cause, whichever came first, assessed up to 3 year
|
|
3-year disease free survival
Tijdsspanne: from operation until recurrence of tumor or death from any cause, whichever came first, assessed up to 3 years
|
Disease free survival is defined as time from initiation to death of any cause within 3years of surgical procedure
|
from operation until recurrence of tumor or death from any cause, whichever came first, assessed up to 3 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Treatment decisions made within multidisciplinary team meeting / tumour board
Tijdsspanne: Prior to surgery
|
For every localization
|
Prior to surgery
|
|
Availability/performance of CT chest, abdomen and pelvis scan performed for pre-operative staging
Tijdsspanne: Prior to surgery
|
For every localization
|
Prior to surgery
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie directeur: Amine Benkabbou, Pr, Moroccan Society of Surgery
- Hoofdonderzoeker: Raouf Mohsine, Pr, National institut of oncology
- Hoofdonderzoeker: Abdelmalek Hrora, Pr, Moroccan Society of Surgery
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- MoroccanSS
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .